The central $3.30 target reflects current sell-side research rather than a single opinion. Data from S&P Global show nine analysts covering ENGN, with an average one-year target of about $3.29 and a range spanning $2.00 to $5.00. Verified individual targets include H.C. Wainwright ($4, Buy) and Piper Sandler ($4, Hold) from mid-October 2026, Wells Fargo ($2, Hold), UBS ($2, Hold), and Leerink Partners ($2, Hold) from September and early October 2026, plus Raymond James ($4, Buy). Two additional firms, Morgan Stanley and Guggenheim, maintain ratings without published price targets.
Views split sharply along durability expectations. After the May 2026 data release, Wells Fargo cut its target from $25 to $2 and downgraded the stock to Equal Weight; Piper Sandler moved to Neutral and lowered its target from $7 to $4; Guggenheim shifted from Buy to Neutral; and H.C. Wainwright kept a Buy rating while slashing its target from $25 to $6, later to $4. The wide $2.00-to-$5.00 range reflects genuine disagreement about whether detalimogene can remain commercially competitive.
enGene Therapeutics Inc. is a Montreal-based clinical-stage biotechnology company developing genetic medicines, led by detalimogene voraplasmid for non-muscle invasive bladder cancer (NMIBC). The company is pre-revenue, with a market capitalization near $104 million and cash of roughly $266 million as of its latest quarter.
ENGN trades near $1.55, at the low end of a 52-week range of $1.40 to $12.25. Reaching the $3.30 target implies upside of about 113%, which qualifies as a very large move. The path would likely require stabilization of efficacy trends, a favorable FDA (Food and Drug Administration) engagement, and renewed confidence that a potential biologics license application remains viable.
Several factors underpin the more constructive targets. Detalimogene demonstrated a favorable safety and tolerability profile, with mostly mild treatment-related adverse events and a low 3.2% progression rate to muscle-invasive disease. The company holds RMAT (Regenerative Medicine Advanced Therapy) and Fast Track designations, and management plans further FDA engagement and additional LEGEND data in the second half of 2026. Its non-viral DDX delivery platform also offers practical advantages such as intravesical administration without cold-chain storage. With cash exceeding its market value, ENGN retains runway to generate more mature data.
The principal obstacle is durability. The 12-month complete response rate of 25% (by Kaplan-Meier estimate) and weaker trends in recent patient cohorts trailed competitors such as Anktiva, cretostimogene, and Adstiladrin. Analysts have questioned whether detalimogene can close the efficacy gap, with one projection cutting peak sales estimates by roughly 65%. A shareholder-rights investigation, ongoing net losses, pre-revenue status, and the risk that regulators decline to accept a filing all represent additional headwinds. Valuation compression in a crowded NMIBC field could keep the stock well below $3.30.
Technically, ENGN remains in a deep downtrend, trading far below its prior highs and under major moving averages. The 52-week low near $1.40 acts as a key support level, while $2.00 and $4.00 — which coincide with the cluster of current analyst targets — represent important psychological and resistance levels. A sustained move above $2.00 would be an early sign of stabilization, while $4.00 marks the upper boundary of most current forecasts.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions vary. Near-term catalysts include fuller LEGEND follow-up data, the outcome of FDA engagement expected in the second half of 2026, and the company's next earnings report, estimated for late December 2026. Investors should watch analyst revisions, cohort consistency, and any regulatory or financing developments, as these will most directly shape whether the $3.30 target remains attainable.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like ENGN, such tools can help traders surface opportunities, monitor existing positions, and detect shifting trends more efficiently than manual review alone. Traders seeking a data-driven edge may find it worthwhile to explore these signals as part of a broader research process.
The question of whether ENGN can reach $3.30 ultimately hinges on detalimogene's durability data and the company's regulatory path. The target is the average of current analyst price targets spanning $2.00 to $5.00, implying a roughly 113% move from today's level — a very large gap that reflects genuine uncertainty. Supportive factors include the drug's safety profile, low progression rate, regulatory designations, and a cash position exceeding the market cap. Against these stand weaker durability versus competitors, analyst downgrades, a shareholder investigation, and pre-revenue status. The wide analyst range signals that no consensus exists on the stock's fate, and investors should focus on upcoming FDA engagement and full LEGEND data before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ENGN has been closely correlated with TRDA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENGN jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To ENGN | 1D Price Change % | ||
|---|---|---|---|---|
| ENGN | 100% | -5.65% | ||
| TRDA - ENGN | 75% Closely correlated | +11.94% | ||
| COGT - ENGN | 48% Loosely correlated | -5.66% | ||
| PHAR - ENGN | 43% Loosely correlated | +0.46% | ||
| INSM - ENGN | 42% Loosely correlated | +2.92% | ||
| ASBP - ENGN | 36% Loosely correlated | +0.06% | ||
More | ||||